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INTRODUCTION
An imbalance in activities between vasodilator (nitric oxide [NO], prostacyclin [PGI 2 ])
and vasoconstrictor (thromboxane, endothelin) pathways contributes to the pathogenesis of pulmonary arterial hypertension (PAH) (Tuder et al, 1999) . Restoration of PGI 2 function is one strategy in the effective management of the disease, and analogs of PGI 2 provide therapeutic benefits in PAH. Activation of the PGI 2 receptor (IP receptor) by PGI 2 analogs leads to vasodilation and reduced proliferation of vascular smooth muscle cells (Gomberg-Maitland and Olschewski, 2008) . Administration of these drugs, however, can be painful and inconvenient for the patient (Humbert et al, 1999 , Sitbon et al, 2002 . In addition, gastric side-effects including abdominal cramping, gastric pain, nausea, vomiting and diarrhea are common in patients treated with PGI 2 analogs (Widlitz et al, 2007) . These compounds are not selective for the IP receptor (Kiriyama et al, 1997; Narumiya et al, 1999; Abramovitz et al, 2000) and gastric irritation may result from activation of other prostanoid receptors that are expressed in the gastro-intestinal tract (Dey et al, 2006 ). Binding assays demonstrate that both iloprost and beraprost have high affinity for EP 1 and EP 3 receptors (Abramovitz et al, 2000; Kiriyama et al, 1997) . These receptor subtypes mediate contraction of rat gastric fundus as evidenced by contraction to (Kuwano et al, 2007) and is an orally available IP receptor agonist that is in clinical development for the treatment of PAH. Selexipag is chemically distinct from analogs of PGI 2 . In vitro, selexipag has high selectivity for the human IP receptor over other prostanoid receptors (Kuwano et al, 2007) . Selexipag is readily hydrolysed to the active metabolite , which is also a potent and selective agonist at IP receptors. ACT-333679 has at least 130-fold higher affinity for the IP receptor over other prostanoid receptors. The receptor selectivity profile of selexipag and ACT-333679 was derived from radioligand displacement studies using recombinant cells engineered to express human prostanoid receptors. Selectivity of selexipag and ACT-333679 for the IP receptor using functional ex vivo and whole body systems has not been systematically evaluated.
This study sought to determine the impact of selectivity of selexipag and ACT-333679 for the IP receptor on gastric function by measuring 1) contraction of rat gastric fundus ex vivo, and 2) gastric emptying and intestinal transport in vivo in response to selexipag and PGI 2 analogs. Reactivity of rat gastric fundus was studied since perturbation of the gastro-intestinal system by PGI 2 analogs is commonly observed in the clinic (Gomberg-Maitland and Olschewski, 2008) and prostaglandins regulate gastric function (Wallace, 2008) . The PGI 2 analogs iloprost, beraprost and treprostinil were studied in comparison with selexipag and metabolite ACT-333679.
Data presented here demonstrate that selexipag and ACT-333679, unlike analogs of PGI 2 , do not affect gastric function, which may help minimize off-target side-effects in the gastro-intestinal system such as nausea and vomiting. Breeding Division (Harlan, Füllinsdorf, Switzerland) . All rats were housed in climatecontrolled conditions with a 12-h light/dark cycle and had free access to normal pelleted rat chow and drinking water in accordance with local guidelines (Basel-Landschaft cantonal veterinary office).
Measurement of receptor mRNA expression.
Expression levels of mRNA encoding prostanoid receptors in the rat gastric fundus were first measured in order to establish that this tissue expressed multiple prostanoid receptor subtypes. Rats were euthanized by CO 2 asphyxiation and the stomach removed. Total RNA was isolated from gastric fundus without mucosa (30 mg samples) using the RNeasy fibrous tissue kit according to the manufacturer's protocol (Qiagen, Germany).
Remaining genomic DNA was digested using the DNAse free kit (Ambion, USA). The quantity of RNA was analyzed using a Nanodrop spectrophotometer (Thermo Fisher, USA) and RNA quality was assessed using an Agilent Bioanalyzer 2100. Total RNA was reverse transcribed using the high capacity cDNA archive kit (Applied Biosystems, USA). QPCR was performed on the ABI 7500 machine using TaqMan probes. The following TaqMan primers and probes from Applied Biosystems and Roche Diagnostics were used for QPCR: DP-Rn00824628_m1, EP1-Rn01432713_s1, EP3-Rn0121735_m1, IP-Rn01764022_m1 and 18s rRNA assay number 4130983E from Applied Biosystems. Rat isolated gastric fundal strips. Following euthanasia, fundal strips were prepared from rats according to the method described by Vane (Vane, 1957) . Briefly, the stomach was excised and the fundus separated from the pyloric antrum. The fundus was opened by cutting along the lesser curvature and the mucosa was carefully removed.
Longitudinal incisions were performed along the length of the fundus to produce strips 
Measurement of gastric emptying and intestinal transport.
The effects of selexipag and beraprost on gastro-intestinal function in vivo were tested.
Rats were fasted overnight. Selexipag, beraprost or drug vehicle were administered by oral gavage and a charcoal meal (1 ml/ rat, 5% carbon powder suspended in 10% arabic concentration causing a 50% reduction in the maximum force generated by sulprostone:
pD' 2 = pD' x + log (X -1), where pD' x is the negative logarithm of the concentration of DBTSA, and X is the ratio of maximal contraction to sulprostone in the absence and presence of DBTSA. The effects of receptor antagonists on contraction of gastric fundus to analogs of PGI 2 were quantified by comparing calculated areas under the agonist concentration-response curves in the absence and presence of antagonists. Statistical comparisons between control and treated groups were performed using student's paired t test (two-tailed). Significance was accepted at P < 0.05.
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RESULTS
Prostanoid receptor mRNA expression and function.
Initial experiments using RT-QPCR established expression of mRNA encoding multiple prostanoid receptors was expressed in rat gastric fundus. A differential expression pattern for receptor mRNA was recorded (figure 1). The highest levels of mRNA encoded the EP 1 receptor, although mRNA for both the IP and EP 3 receptors was also expressed. TP and DP receptor mRNA expression was detectable but to an almost negligible degree.
In order to test the functionality of EP 1 and EP 3 receptors, the response of isolated gastric fundal strips to the EP 3 /EP 1 receptor agonist sulprostone was measured.
Sulprostone contracted rat gastric fundus in a concentration-dependent manner (10 -10 M -10 -5 M). Contraction to sulprostone was significantly inhibited by DBTSA (10 -5 M)
( Table 1 ). The calculated pD' 2 value for DBTSA was 4.7 ± 0.1 (n = 6). Also, the EP 1 receptor antagonist SC19220 (3 x 10 -5 M) caused a significant right-ward displacement of the concentration-contraction curve to sulprostone (Table 1) .
IP receptor selectivity and gastric fundus.
The impact of selectivity for the IP receptor on gastric responsiveness was first studied by measuring contraction of rat gastric fundus to selexipag and ACT-333679 in comparison to analogs of PGI 2 . The IP receptor selective compounds selexipag and ACT-333679 did not contract rat fundal strips above baseline force, even at concentrations up to 10 -3 M (figure 2). Indeed, both compounds evoked weak relaxation of baseline force both in the absence and presence of the IP receptor antagonist CAY10441 (3 x 10 -6 M) (figure 3).
This article has not been copyedited and formatted. The final version may differ from this version. Selexipag and ACT-333679 were shown to be pharmacologically active in rat since both compounds evoked concentration-dependent relaxation of precontracted rat pulmonary artery (pEC 50 values of 5.38 ± 0.03 and 5.61 ± 0.06, respectively; n = 6). Similarly, iloprost relaxed rat pulmonary artery (control pEC 50 value of 6.6 ± 0.1, n = 4). Relaxation to iloprost was significantly inhibited by CAY10441 (10 -6 M) (areas under curves:
control vs treated P < 0.001, n = 4).
In contrast to the findings with selexipag and ACT-333679, the non-selective PGI 2 analogs iloprost and beraprost induced concentration-dependent contraction of rat fundal strips (figure 4). Also, treprostinil evoked a small contraction of gastric fundus at the highest concentration tested (10 -4 M). The, contraction to iloprost and beraprost was significantly inhibited by the EP 3 receptor antagonist DBTSA (10 -5 M) (iloprost P < 0.05, beraprost P < 0.01; figure 4A , B). Contraction to the highest concentration of treprostinil tested was also significantly inhibited by DBTSA (P < 0.05; figure 4C ). The IP receptor CAY10441 did not significantly alter contraction of rat fundal strips to the PGI 2 analogs ( figure 4D-F) . The role of EP 1 receptors in the contraction to PGI 2 analogs was investigated using the antagonist SC19220. Contraction to iloprost and beraprost, but not treprostinil, was inhibited by SC19220, as indicated by significant reductions in the areas under the curves (iloprost control vs treated, P < 0.05; beraprost control vs treated P < 0.05) ( figure 5A and D) . The inhibitory effect of SC19220 on contraction to iloprost and beraprost was confirmed using the congener SC51322 (10 -6 M) (areas under curves:
iloprost control vs treated, P < 0.001, n = 5; beraprost control vs treated, P < 0.05, n = 5).
Antagonism of TP receptors and DP 1 receptors using GR32191B and BW A868C, respectively, did not significantly inhibit contraction of rat fundal strips to PGI 2 analogs This article has not been copyedited and formatted. The final version may differ from this version. control vs treated, P > 0.05, n = 4).
Gastro-intestinal activity in rats
The effects of selexipag and beraprost were next compared on the rates of gastric emptying and intestinal transport. Doses of selexipag and beraprost were chosen to attain concentrations in the stomach that reflect the highest concentrations used in contractility studies ex vivo. Calculation of doses for in vivo experiments was based on a rat stomach volume of 2.5 ml. Preliminary experiments validated the charcoal assay for measurement of intestinal transport using standard reference drugs. The inhibitor of acetylcholinesterase neostigmine accelerated gastro-intestinal transport (122 ± 4 % versus control 100%; n = 12-13, P < 0.01), whereas the non-selective muscarinic receptor antagonist atropine inhibited gastro-intestinal transport (78 ± 5 % versus control 100%, n = 10-13, P < 0.01). Selexipag did not retard gastric emptying or intestinal transport at 1 or 3 mg/kg (figure 6). Also, beraprost at a dose of 0.03 mg/kg had no significant effect on emptying of the stomach or rate of intestinal transport compared to vehicle control. A higher dose of beraprost (0.1 mg/kg), however, significantly slowed gastric emptying and intestinal transport (P < 0.05; figure 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. . Also, it seems unlikely that conversion of selexipag to metabolite ACT-333679 occurred over the duration of the experiment, given that responses to both compounds were similar, and that the mucosa was removed, negating any mucosal hydrolytic activity (Fukuhara et al, 1996) . The absence of significant responses to selexipag and ACT-333679 in rat gastric fundus did not extend to other tissues in this species. Pharmacological activity of both compounds was confirmed by measuring concentration-dependent relaxation of the rat pulmonary artery pre-contracted with PGF 2α . The calculated pEC 50 value for relaxation is in good agreement with previous findings (Kuwano et al, 2008) . The lack of efficacy of selexipag and ACTThis article has not been copyedited and formatted. The final version may differ from this version. 333679 on gastric reactivity relates directly to the high degree of IP receptor selectivity of these compounds. The PGI 2 analog cicaprost, which is also more selective than other PGI 2 analogs for the IP receptor (Abramovitz et al, 2000) , also fails to contract rat gastrointestinal smooth muscle at sub-micromolar concentrations (Qian and Jones, 1995) .
The analogs of PGI 2 tested in this study contracted rat gastric fundus. Iloprost and beraprost evoked robust contractile responses, whereas weak contraction to treprostinil was observed at the highest concentration tested. Maximal responses to PGI 2 analogs were inferior to that evoked by the EP 3 /EP 1 receptor agonist sulprostone, supporting the previous findings of Dong et al (1986) . Contraction to all PGI 2 analogs tested here was sensitive to antagonism of EP 3 receptors. These data are consistent with findings in the EP3 -/-mouse model where contraction of fundal strips to PGI 2 is abolished (Okada et al, 2000) . Iloprost and beraprost both bind EP 3 receptors with high affinity (Abramovitz et al, 2000 , Kuwano et al, 2007 and might be expected to activate EP 3 receptors at concentrations used in this study. Affinity data for treprostinil at non-IP receptors is not available, but the observation that treprostinil contracted fundus at high concentration via activation of EP 3 receptors suggests that this PGI 2 analog is also not selective for the IP receptor.
A role for the EP 1 receptor subtype in the contractile response to PGI 2 analogs was also considered given that the level of EP 1 receptor mRNA was highly expressed in gastric fundus, and iloprost has high affinity for this receptor subtype (equal K i values at EP 1 and IP receptors) (Abramovitz et al, 2000) . Indeed, the EP 1 receptor antagonist SC19220 caused a statistically significant inhibition of contraction to both iloprost and beraprost. These data are consistent with the findings of Bennett et al (1980) . DBTSA may also antagonize TP and DP 1 receptors at the concentration used in this study (Gallant et al, 2002) . The possibility that antagonism of TP receptors contributed to the effect of DBTSA is unlikely, however, since the selective TP receptor antagonist GR32191B did not significantly inhibit contraction. Similarly, antagonism of DP 1 receptors by DBTSA can be dismissed since the DP 1 receptor antagonist BWA868C
did not influence contraction to any of the PGI 2 analogs tested. Furthermore, although contractile FP receptors may be present in gastric fundus (Dong et al, 1986) , the selective FP receptor antagonist AL8810 did not significantly affect contraction to any of the PGI 2 analogs tested.
The second goal of this study was to establish the impact of selectivity for the IP receptor on gastric performance in vivo. To this end, the effects of selexipag and beraprost on the rates of gastric emptying and intestinal transport were compared. Doses of selexipag and beraprost were chosen to attain concentrations in the stomach that reflect the high concentrations studied using the isolated gastric fundus. Also, the doses chosen effectively lower pulmonary arterial pressure and reduce ventricular hypertrophy in a rat model of PAH (Kuwano et al, 2008) . Selexipag at 1 and 3 mg/kg, doses in the stomach that are equivalent to 2 x 10 -4 M and 6 x 10 -4 M, respectively, had no effect on the rate of Normal gastric emptying requires the coordinated and rhythmic contraction of the stomach (Pal et al, 2007) . Disruption of gastric smooth muscle activity underlies nausea and vomiting (Holmes et al, 2009 ). Thus, contraction of gastro-intestinal smooth muscle, as observed in this study, has important implications for the oral tolerability of a compound. Several lines of evidence support a role for EP 3 receptors in the perturbation of gastric function. The EP 3 receptor agonist sulprostone evokes emesis and diarrhea in the ferret (Kan et al, 2002) . Iloprost also induces emesis in the ferret, whereas the selective IP receptor agonist cicaprost has no effect (Kan et al, 2002) . Moreover, in the present study, iloprost evoked EP 3 receptor-dependent contraction of rat fundus, which may disturb the regulated and coordinated waves of contraction in the stomach leading to dysregulation of food mixing and gastric emptying (Pal et al, 2007) . Importantly, gastric muscular dysrhythmias are initiated by EP 3 receptor agonists in the mouse (Forrest et al, 2009 ). Studies on emesis cannot be performed in rodents (Holmes et al, 2009 ) but delayed gastric emptying and increased chewing and swallowing are observed in the rat in response to substances that would be expected to be emetic in other species such as the ferret (Andrews and Horn, 2006) . Delayed gastric emptying in the rat is considered as a surrogate marker for vomiting (Bradner and Schurig, 1981) . The finding in the present study that beraprost contracted gastric fundus via activation of EP 3 receptors and slowed gastric emptying is consistent with the emetic properties of the drug in the clinic.
In conclusion, the results of this study demonstrate that the selective IP receptor agonist selexipag can be distinguished from PGI 2 analogs in terms of gastric reactivity in 
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